At the center of the debate are the growing number of manufacturer demands for claims data as a condition of 340B pricing.
Natalie P. Crow
Advertisement
Natalie P. Crow, associate with Buchanan Ingersoll & Rooney
Articles by Natalie P. Crow
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Drug Topics
1
CVS Plans to Split Off Its Retail Pharmacies, Keeping Specialty Operations
2
Patients Report Significant Value in Enhanced Pharmacy Services
3
GLP-1s Outperform Metformin in Prediabetes Risk, MACE
4
An Inside Look at the First AI-Prescribing Technology
5